Disc Medicine, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases,...
Gilead Sciences, Inc. and CymaBay Therapeutics, Inc. announced a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or...
Domain Therapeutics, a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors announces the appointment of Sean A. MacDonald...
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
EnteroBiotix Limited (“EBX”), a clinical stage biopharmaceutical company with the premier platform for full-spectrum microbiome therapeutics, announced the appointments of Dr James Barnes as...
